CoChat

Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies

Sajatovic, Martha, Forester, Brent P., Tsai, Joyce, Kroger, Hans, Pikalov, Andrei, Cucchiaro, Josephine, Loebel, Antony · 2016 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record.

Abstract

OBJECTIVE: The aim of this post hoc analysis was to evaluate the efficacy of lurasidone in patients aged 55 years and older with bipolar depression. METHODS: A post hoc analysis was performed on the older adult subgroup (n = 142) of outpatients meeting DSM-IV-TR criteria for bipolar I depression in 2 placebo-controlled, 6-week, randomized, double-blind studies conducted from 2009-2012: a monotherapy study comparing fixed flexible-dose ranges of lurasidone 20-60 mg/d or 80-120 mg/d with placebo and an adjunctive therapy study comparing flexible doses of lurasidone 20-120 mg/d with placebo adjunctive to either lithium or valproate. The primary endpoint was mean change at week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. RESULTS: In the randomized sample, the proportion of older adults was 88/505 (17.4%) in the monotherapy study and 54/348 (15.5%) in the adjunctive therapy study. In the older adult subgroup in the monotherapy study, mean change at week 6 in the MADRS was significantly greater for lurasidone versus placebo (-14.8 vs -7.1; P = .003; effect size, 0.83; pooled doses), and in the adjunctive therapy study, mean change for lurasidone was not significantly different from placebo (-13.9 vs -11.1; P = .398; effect size, 0.26). Discontinuation rates due to adverse events for lurasidone versus placebo were similar for the monotherapy (6.8% vs 6.9%) and adjunctive therapy (3.8% vs 7.1%) studies. Lurasidone had minimal effects on metabolic laboratory values. CONCLUSIONS: The results of these post hoc analyses, which assessed the efficacy of lurasidone in older adults with bipolar disorder, found that monotherapy was significantly effective while adjunctive therapy was not associated with significant improvement. Both monotherapy and adjunctive therapy with lurasidone were safe and well-tolerated in this older adult population. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00868699, NCT00868452.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.15m10261

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 55

Metadata

Authors
Sajatovic, M., Forester, B. P., Tsai, J., Kroger, H., Pikalov, A., Cucchiaro, J., & Loebel, A.
Affiliations
  • University Hospitals Cleveland Medical Center (US)
  • Harvard University (US)
  • Sunovion (United States) (US)
Corresponding author
Sajatovic, Martha
Venue
The Journal of Clinical Psychiatry
Published
2016-08-16
Volume
77
Issue
10
Pages
e1324-e1331
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2514389710
Cited by
54
References
0
Citations by year
2026: 4 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 8 · 2021: 12 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 8
FWCI
4.45
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
lurasidone, bipolar depression, bipolar I disorder, older adults, monotherapy, adjunctive therapy, lithium, valproic acid, antidepressant efficacy, drug safety and tolerability
MeSH terms
Lurasidone Hydrochloride, Aged, Bipolar Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Valproic Acid, Lithium Carbonate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies. https://app.cochat.ai/papers/10.4088/jcp.15m10261
The paper
Sajatovic, M., Forester, B. P., Tsai, J., Kroger, H., Pikalov, A., Cucchiaro, J., & Loebel, A. (2016). Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.15m10261

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.